Yanqiao Zhang

Harbin Medical University - Cancer Hospital

China

SCHOLARLY PAPERS

1

DOWNLOADS

34

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (1)

1.

Safety, Efficacy and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial

Number of pages: 139 Posted: 26 Nov 2019
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Harbin Medical University - Cancer Hospital, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, OrigiMed, Inc., Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD and Peking University - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing)
Downloads 34 (631,882)

Abstract:

Loading...

Neuroendocrine neoplasm, NET, NEC, PD-1,toripalimab